Appendiceal Cancers: Clinical Trials

2 trials for Appendiceal Cancers, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting. 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 11Recruiting 1

Follow Appendiceal Cancers: new trials by email Literature Review of Appendiceal Cancers trials Research Report on Appendiceal Cancers

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months - Advanced Small Intestine Cancer, Appendiceal Cancers
Phase 1RecruitingThe Methodist Hospital Research Institute222026-09-182026-11-03
An International Study on Pediatric Patients With Rare Tumors.
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
RecruitingAzienda Ospedaliera di Padova62502025-01-252025-07-18

Narrower conditions

Adrenal Cortex Neoplasms (1)  ·  Esthesioneuroblastoma, Olfactory (1)  ·  Gastrointestinal Stromal Tumors (1)  ·  Melanoma (1)  ·  Mesothelioma (1)  ·  Nasopharyngeal Carcinoma (1)  ·  Pancreatic Neoplasms (1)  ·  Pleuropulmonary blastoma (1)  ·  Thymus Neoplasms (1)  ·  Thyroid Neoplasms (1)

Broader conditions

Adenoma (1)  ·  Adrenal Cortex Diseases (1)  ·  Adrenal Gland Diseases (1)  ·  Adrenal Gland Neoplasms (1)  ·  Carcinoma (1)  ·  Cranial Nerve Diseases (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Gastrointestinal Diseases (1)  ·  Gastrointestinal Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Lymphatic Diseases (1)

Interventions

Fluorouracil (1)  ·  Oxaliplatin (1)  ·  irinotecan sucrosofate (1)

Sponsors

Azienda Ospedaliera di Padova (1)  ·  The Methodist Hospital Research Institute (1)

Countries

Italy (1)  ·  United States (1)

Top investigators

Abdullah Esmail, MD (1)  ·  Gianni Bisogno, MD (1)